Protective effect of resveratrol against methotrexate-induced oxidative stress in the small intestinal tissues of rats

ArticleAçık Erişim

Özet

The effect of resveratrol on the damage induced by methotrexate (MTX) in rat duodenum and jejunum tissue was investigated and evaluated in comparison with famotidine. The rats were divided into four groups as healthy group (HG), resveratrol+MTX (RMTX) group, famotidine+MTX (FMTX) group and the control group which received MTX (MTXC). RMTX group was given resveratrol 25 mg/kg and FMTX group famotidin 25 mg/kg, while MTXC and HG groups were orally administered distilled water once a day for 30 days. The rats in RMTX, FMTX and MTXC groups were given MTX of 5 mg/kg dose by the same way for 30 days. At the end of this period, amount of MDA, 8-OH/Gua and tGSH, and MPO gene expression were measured in the duodenal and jejunal tissues and the results were histopathologically evaluated. Resveratrol and famotidine were found to significantly prevent elevation of the MDA, 8-OH/Gua and MPO parameters with MTX and decrease of the levels of tGSH in the duodenal and jejunal tissues. Both drugs prevented severe damage to the villus and crypt epithelium in the duodenum and jejunum, congestion and hemorrhage, inflammatory cell infiltration and necrosis in the mucosa and submucosa due to MTX administration. Resveratrol could be considered in the clinical practice for treatment of the tissue damage in the intestines due to use of MTX, in comparison with famotidine. Resveratrol may be more advantageous than famotidine in long-term use against MTX toxicity since it does not inhibit gastric acid secretion. © 2015 E-Century Publishing Corporation. All rights reserved.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/15145Resmi atıflarda kullanılan kalıcı adres
Tam Kayıt
AlanDeğerDil
dc.contributor.authorArslan, Aynur
dc.contributor.authorOzcicek, Fatih
dc.contributor.authorCimen, Ferda Keskin
dc.contributor.authorAltuner, Durdu
dc.contributor.authorYarali, Oguzhan
dc.contributor.authorKurt, Nezahat
dc.contributor.authorTumkaya, Levent
dc.contributor.authorOzturk, Cengiz
dc.contributor.authorSuleyman, Halis
dc.date.accessioned2026-10-18T20:29:56.263070249Z
dc.date.available2026-10-18T20:29:56.263070249Z
dc.date.issued2015
dc.description.abstractThe effect of resveratrol on the damage induced by methotrexate (MTX) in rat duodenum and jejunum tissue was investigated and evaluated in comparison with famotidine. The rats were divided into four groups as healthy group (HG), resveratrol+MTX (RMTX) group, famotidine+MTX (FMTX) group and the control group which received MTX (MTXC). RMTX group was given resveratrol 25 mg/kg and FMTX group famotidin 25 mg/kg, while MTXC and HG groups were orally administered distilled water once a day for 30 days. The rats in RMTX, FMTX and MTXC groups were given MTX of 5 mg/kg dose by the same way for 30 days. At the end of this period, amount of MDA, 8-OH/Gua and tGSH, and MPO gene expression were measured in the duodenal and jejunal tissues and the results were histopathologically evaluated. Resveratrol and famotidine were found to significantly prevent elevation of the MDA, 8-OH/Gua and MPO parameters with MTX and decrease of the levels of tGSH in the duodenal and jejunal tissues. Both drugs prevented severe damage to the villus and crypt epithelium in the duodenum and jejunum, congestion and hemorrhage, inflammatory cell infiltration and necrosis in the mucosa and submucosa due to MTX administration. Resveratrol could be considered in the clinical practice for treatment of the tissue damage in the intestines due to use of MTX, in comparison with famotidine. Resveratrol may be more advantageous than famotidine in long-term use against MTX toxicity since it does not inhibit gastric acid secretion. © 2015 E-Century Publishing Corporation. All rights reserved.
dc.identifier.endpage10500
dc.identifier.issn1940-5901
dc.identifier.issue7
dc.identifier.scopus2-s2.0-84940688784
dc.identifier.startpage10491
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/15145
dc.identifier.volume8
dc.language.isoen
dc.publisherE-Century Publishing Corporation
dc.relation.ispartofInternational Journal of Clinical and Experimental Medicine
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectOxidative stress
dc.subjectResveratrol
dc.subjectSmall intestine
dc.subjectcomplementary DNA
dc.subjectfamotidine
dc.subjectglutathione
dc.subjectmalonaldehyde
dc.subjectmethotrexate
dc.subjectmyeloperoxidase
dc.subjectanimal tissue
dc.subjectantioxidant activity
dc.subjectArticle
dc.subjectcell infiltration
dc.subjectcontrolled study
dc.subjectdigestive system ulcer
dc.subjectduodenum disease
dc.subjectgene expression
dc.subjecthigh performance liquid chromatography
dc.subjecthistopathology
dc.subjectjejunum disease
dc.subjectmale
dc.subjectnonhuman
dc.subjectrat
dc.subjectreal time polymerase chain reaction
dc.subjecttissue injury
dc.titleProtective effect of resveratrol against methotrexate-induced oxidative stress in the small intestinal tissues of rats
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus20
rdl.source.indexSCOPUS